Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Warren Chumley

Clinical Neurophysiology Lexington, KY Medical Doctor

NPI 1902853617 CMS profile 177515

1021 Majestic Drive, Suite 200, Lexington, KY 40513

Open in the dashboard

General payments

$288,359

1,199 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$359,995 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Warren Chumley of Lexington, KY is reported in the CMS Open Payments database as having received $288,359 across 1,199 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $359,995 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Clinical Neurophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,779 175
2024 General $19,728 157
2023 General $23,554 126
2022 General $52,709 127
2021 General $64,458 117
2020 General $43,932 128
2019 General $66,198 369

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Warren Chumley
  • Clinical Neurophysiology median
  • Middle half of Clinical Neurophysiology
  • National median

In program year 2025, general payments to Warren Chumley were reported at $17,779. Among 259 Clinical Neurophysiology profiles paid that year, the median was $435 and the middle half received between $121 and $1,917.

Show as a table
Year Warren Chumley Clinical Neurophysiology median Middle half National median
2019 $66,198 $306 $88–$1,636 $163
2020 $43,932 $299 $85–$1,847 $114
2021 $64,458 $325 $96–$2,308 $132
2022 $52,709 $395 $106–$1,957 $149
2023 $23,554 $388 $120–$1,718 $160
2024 $19,728 $471 $137–$1,931 $164
2025 $17,779 $435 $121–$1,917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $103,944 306 payments
  2. Allergan Inc. $61,894 124 payments
  3. Amgen Inc. $30,991 54 payments
  4. Teva Pharmaceuticals USA, Inc. $26,566 121 payments
  5. Lilly USA, LLC $16,760 69 payments
  6. Biohaven Pharmaceuticals, Inc. $11,889 31 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $9,033 51 payments
  8. Lundbeck LLC $5,580 11 payments
  9. Mallinckrodt Enterprises LLC $4,487 11 payments
  10. Alexion Pharmaceuticals, Inc. $4,422 23 payments
  11. Other $12,793 398 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $240,649 117 payments
  2. Food and Beverage $21,650 1,005 payments
  3. Consulting Fee $10,309 8 payments
  4. Travel and Lodging $8,389 60 payments
  5. Honoraria $7,100 3 payments
  6. Education $262 6 payments
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $61,428 139 payments
  2. BOTOX Neuroscience $58,577 55 payments
  3. AIMOVIG $30,936 57 payments
  4. QULIPTA $25,246 107 payments
  5. NURTEC ODT $20,921 82 payments
  6. UBRELVY Neuroscience $14,448 32 payments
  7. BOTOX Neuroscience $14,427 20 payments
  8. AJOVY Central Nervous System $14,262 34 payments
  9. Ajovy Central Nervous System $12,106 72 payments
  10. EMGALITY $9,870 61 payments
  11. Other $34,780 727 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

5,362

Median for Neuropsychiatry: 88

Drug cost

$2,276,602

Median for Neuropsychiatry: $2,689

Branded share of claims

39.1%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 12 $212,079
Ubrelvy Ubrogepant Brand 131 $208,507
Ingrezza Valbenazine Tosylate Brand 25 $203,172
Nurtec Odt Rimegepant Sulfate Brand 107 $189,768
Gilenya Fingolimod Hcl Brand 18 $178,836
Emgality Pen Galcanezumab-Gnlm Brand 185 $160,962
Qulipta Atogepant Brand 141 $158,470
Rebif Rebidose Interferon Beta-1a/Albumin Brand 15 $154,681
Avonex Pen (4 Pack) Interferon Beta-1a Brand 15 $142,468
Zeposia Ozanimod Hydrochloride Brand 14 $124,458

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$203,815

Of which drugs: $148,521

Medicare patients

204

Average age 68

Services billed

30,087

144 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 50%
Depression 45%
Diabetes 30%
Ischemic heart disease 28%
Chronic kidney disease 19%
COPD 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 42 25,900 $126,711

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$13,355 19 25,900
UBRELVY
$4,369 131 —
QULIPTA
$311 141 —
ZAVZPRET
$219 — —
KESIMPTA
$206 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Neurophysiology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record